{"filing":{"accession_number":"0001193125-26-331516","cik":"0001374690","ticker":"LRMR","company_name":"Larimar Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"lrmr-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526331516/lrmr-20260804.htm"},"events":[{"id":23863,"run_id":21584,"accession_number":"0001193125-26-331516","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Larimar Therapeutics announced its second quarter 2026 financial results and operational highlights on August 4, 2026, disclosing a net loss of $32.8 million for Q2 2026 (versus $26.2 million for Q2 2025), cash position of $156.3 million, detailed expense breakdowns, cash runway projections, and material clinical milestones including initiation of a rolling BLA submission and expected Phase 3 dosing in Q3 2026.","company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24212,"accession_number":"0001193125-26-331516","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Larimar's second quarter 2026 financial results and operational highlights. The filing explicitly states \"On August 4, 2026, Larimar Therapeutics, Inc. announced its financial results and operational highlights for the second quarter ended June 30, 2026\" under Item 2.02, with the press release furnished as Exhibit 99.1. The disclosure includes net loss figures ($32.8 million for Q2 2026 vs. $26.2 million for Q2 2025), detailed R\u0026D and G\u0026A expense breakdowns, cash position ($156.3 million), and cash runway projections—all hallmarks of a quarterly earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:23:16.150811+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24213,"accession_number":"0001193125-26-331516","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 8.01 disclosure references an updated slide presentation posted on August 4, 2026, but the substantive content disclosed is Larimar's second quarter 2026 financial and business update, including Q2 2026 net loss of $32.8 million, cash position of $156.3 million, and material clinical and regulatory milestones (rolling BLA submission initiated, Phase 3 dosing expected Q3 2026). The attached EX-99.1 is a formal earnings release with financial results and operational highlights. This is a quarterly earnings disclosure material to investors assessing the company's financial condition and clinical progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:23:16.150811+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24212,"accession_number":"0001193125-26-331516","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Larimar's second quarter 2026 financial results and operational highlights. The filing explicitly states \"On August 4, 2026, Larimar Therapeutics, Inc. announced its financial results and operational highlights for the second quarter ended June 30, 2026\" under Item 2.02, with the press release furnished as Exhibit 99.1. The disclosure includes net loss figures ($32.8 million for Q2 2026 vs. $26.2 million for Q2 2025), detailed R\u0026D and G\u0026A expense breakdowns, cash position ($156.3 million), and cash runway projections—all hallmarks of a quarterly earnings announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:23:16.150811+00:00","company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","filing_date":"2026-08-04"},{"id":24213,"accession_number":"0001193125-26-331516","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 8.01 disclosure references an updated slide presentation posted on August 4, 2026, but the substantive content disclosed is Larimar's second quarter 2026 financial and business update, including Q2 2026 net loss of $32.8 million, cash position of $156.3 million, and material clinical and regulatory milestones (rolling BLA submission initiated, Phase 3 dosing expected Q3 2026). The attached EX-99.1 is a formal earnings release with financial results and operational highlights. This is a quarterly earnings disclosure material to investors assessing the company's financial condition and clinical progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:23:16.150811+00:00","company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","filing_date":"2026-08-04"}]}